SPRC SciSparc Ltd.
Listings ·
SciSparc reported $4,436 thousand of cash and a $6,051 thousand net loss for the six months to June 30, 2026. Its own going concern note says these factors raise substantial doubt about its ability to continue as a going concern.
SciSparc put in C$2.7 million, half the total, and says it will hold approximately 44.6% of NeuroThera afterward. NeuroThera plans to use the money for general working capital.
Nasdaq staff said on May 7, 2026 that SciSparc now meets the $2,500,000 stockholders' equity standard, but the letter is conditional. Delisting is possible if the company's next periodic report does not show compliance.
NeuroThera would issue 56,600,000 of its own shares, valued at approximately $9,459,954.20, plus up to $2,500,000 in earn-out payments. The release does not say what the issuance would do to SciSparc's approximately 75% stake in NeuroThera.
| Line | FY2020 | FY2019 |
|---|---|---|
| Net income (loss) | -$3.5 million | -$4.7 million |
Our latest story on this, dated May 11, 2026: "SciSparc gets conditional Nasdaq compliance letter on stockholders' equity". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 30, 2026: "SciSparc reports $4,436 thousand in cash and $6,051 thousand loss for first half". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 18, 2026: "SciSparc unit NeuroThera Labs completes C$5.4 million private placements". The story links the filing or release it is based on. Read the story.
SciSparc Ltd. trades under the ticker SPRC on NASDAQ.
SciSparc Ltd. is listed on NASDAQ.
The SEC Central Index Key (CIK) for SciSparc Ltd. is 1611746. Its filings are on SEC EDGAR.
365,444 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-04-29.
Our directory records SciSparc Ltd. under Israel.
Our directory classifies SciSparc Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for SciSparc Ltd. is IL0010951403.
aibio.space lists SciSparc Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as L3.
SciSparc Ltd. reported a net loss of $3.5 million for the fiscal year ended Dec 31, 2020, per its annual report to the SEC.
Our latest story on SciSparc, dated Sep 30, 2026: "SciSparc reports $4,436 thousand in cash and $6,051 thousand loss for first half". SciSparc reported $4,436 thousand of cash and a $6,051 thousand net loss for the six months to June 30, 2026. Its own going concern note says these factors raise substantial doubt about its ability to continue as a going concern. Source.
From our story of Sep 30, 2026: Its own going concern note says these factors raise substantial doubt about its ability to continue as a going concern. Source.
Reported a reverse stock split. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a merger or acquisition agreement. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a merger or acquisition agreement. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a merger or acquisition agreement. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a merger or acquisition agreement. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio